August 5, 2020 7:24pm

The firing range is still open as the all-clear has not sounded

Pre-open indication results: 2 HITs and 1 MISS

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I say today what others won't, so you can do what others can't; I put into context what is relevant for investors

Subscription is coming, my gift to you however, I've kept RMi subscription FREE during these COVID-19 and volatile times!


The Dow closed UP +372.84 points (+1.39%), the S&P closed UP +21.26 points (+0.64%) while the NASDAQ closed UP +57.23 points (+0.52%)

 

Pre-open indication results: 2 HITS < Editas Medicine (EDIT +$0.61), Pluristem (PSTI -$0.27)> and 1 MISS < Biostage (BSTG +$0.06)>

 

Henry’omics:

Indexes rose on the back of coronavirus vaccine hopes and continuing stimulus negotiations. However, gains were capped as July private payrolls data disappointed and lawmakers continued negotiations on a new virus stimulus package.

 

This a.m. I stated in this a.m.’s newsletter - RegMed Investors’ (RMi) pre-open: RegMed Investors’ (RMi) pre-open: we are on the threshold of … what? … https://www.regmedinvestors.com/articles/11487 .

Also, this a.m.’s Biostage (BSTG) Chronicles also offered a warning especially their “art of deceptions” re past PPP loan and future of debt and possible non-compliance as the soon to be approved stimulus bill includes an INELIGIBILITY warning of future loans with Chinese resident’s role on board of directors (BOD) – three (3) on the BOD of BSTG <read a.m. post for who> and possibilities of non-forgiveness of the $404,211.00 already loaned through Bank of America.

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Wednesday opened positive at 17/14 and 4 flats, stayed positive at the mid-day at 19/15 and 1 flat, closing positive at 19/15and 1 flat;
  • Tuesday opened negative at 8/25 and 2 flats, stayed negative at the mid-day at 13/21 and 1 flat, closing negative at 13/20 and 2 flats;
  • Monday opened positive at 27/6 and 2 flats, stayed positive at the mid-day at 25/3 and 2 flats, closing positive at 31/1 and 3 flats;

 

Key metrics:

  • Sector volume was LOW with 2 of the 19-upside having higher than the 3-month average volume and the 5 of 15-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 19-upside were +0.31% (NTLA) to +6.12% (CLBS) while the 15-downside ranged -0.06% (CRSP) to -5.35% (VCEL); 

 

Hammered in today’s market:

  • ReNeuron (RENE.L), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Vericel (VCEL), Global Blood Therapeutics (GBT) to name 5 of the 15 declining of the 35 covered

Jumping with share pricing momentum:

  • Sage Therapeutics (SAGE), Editas Medicine (EDIT) Adverum Biotechnologies (ADVM), AxoGen (AXGN), Cellectis SA (CLLS), to name 5 of the 19 trading up of 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed down -0.29% and XBI also closed up +0.72%
  • Tuesday, the IBB closed down -0.64% and XBI also closed down -0.31%
  • Monday, the IBB closed up +3.13% and XBI also closed up +4.20%

 

Wednesday’s (10 of 19) incliners:

  • Sage Therapeutics (SAGE +$0.91 after Tuesday’s +$3.37);
  • Editas Medicine (EDIT +$0.61 after Tuesday’s +$0.31 and Monday’s +$2.21);
  • Adverum Biotechnologies (ADVM +$0.560;
  • Cellectis SA (CLLS +$0.52);
  • Voyager Therapeutics (VYGR +$0.46 after Tuesday’s -$0.98);
  • Regenxbio (RGNX +$0.45 after Tuesday’s -$0.59);
  • Bellicum Pharmaceuticals (BLCM +$0.37);
  • AxoGen (AXGN +$0.31 after Tuesday’s +$0.53);
  • Mesoblast (MESO +$0.28 after Tuesday’s +$1.08);
  • Precigen (PGEN +$0.27 after Tuesday’s +$0.16);

Wednesday’s (10 of 15) decliners:

  • ReNeuron (RENE.L -$2.50);
  • Alnylam Pharmaceuticals (ALNY -$2.32 after Tuesday’s +$0.46 and Monday’s +$6.54);
  • Ionis Pharmaceuticals (IONS -$2.32);
  • Vericel (VCEL -$0.90 after Tuesday’s -$0.37);
  • Global Blood Therapeutics (GBT -$0.86 after Tuesday’s -$1.72 and Monday’s +$3.00);
  • Ultragenyx (-$0.71 after Tuesday’s +$0.63 and Monday’s +$5.38);
  • Homology Medicine (FIXX -$0.66 after Tuesday’s -$0.55);
  • uniQure NV (QURE -$0.42);
  • bluebird bio (BLUE -$0.38 after Tuesday’s -$0.34 and Monday’s +$2.08);
  • Brainstorm Cell Therapeutics (BCLI -$0.28 after Tuesday’s -$0.69);

Closing flat: 1 – Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: comparisons

  • Wednesday’s percentage (%) of the 19-upside were +0.31% (NTLA) to +6.12% (CLBS) while the 15-downside ranged -0.06% (CRSP) to -5.35% (VCEL); 
  • Tuesday’s percentage (%) of the 13-upside were +0.08% (IONS) to +7.52% (MESO) while the 20-downside ranged -0.10% (BLFS) to -8.90% (ADRO); 
  • Monday’s percentage (%) of the 31-upside were +1.33% (AGTC) to +8.24% (CRSP) while the 1-downside was -14.80% (BSTG); 

 

Sentiment and a few daily indicators:

Washington could be nearing a key compromise on a second coronavirus relief bill, with the White House appearing to bend on extended unemployment benefits.

  • Wednesday 4.7 cases
  • Tuesday 4.71 cases
  • Monday 4.66 cases,

Wednesday’s death rate totaled 157,186 after Tuesday’s 155,478 and Monday’s 154,860 <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Wednesday: 2 out of the 19-upside had higher than the 3-month average volume;
  • Tuesday: 2 out of the 13-upside had higher than the 3-month average volume;
  • Monday: 8 out of the 31-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.77 points or -3.24% at 22.99
  • Tuesday was down -0.52 points or -2.14% at 23.76
  • Monday was down -0.18 points or -0.74% at 24.28

Downside volume:

  • Wednesday: 5 out of the 15-downside had higher than the 3-month average volume;
  • Tuesday: 2 out of the 20-downside had higher than the 3-month average volume;
  • Monday: 1 out of the 1-downside had higher than the 3-month average volume;

 

August, the second month of Q3 …

Wednesday closed positive with 19 advancers, 15 decline and 1 flat

Tuesday closed negative with 13 advancers, 20 decline and 2 flats

Monday (8/3) closed positive with 31 advancers, 1 decline and 3 flats

 

The Bottom line:  

We are in the middle of a storm of earnings announcements this week … which will open the kimono of LPS (loss-per-share) and visibility of development status and revenue’s expectation versus estimates.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.